Legend Biotech/$LEGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
- Ticker
- $LEGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,200
- Headquarters
- Somerset, United States
- Website
- legendbiotech.com
Legend Biotech Metrics
BasicAdvanced
$4.2B
-
-$0.50
0.40
-
Price and volume
Market cap
$4.2B
Beta
0.4
52-week high
$37.50
52-week low
$16.24
Average daily volume
2.1M
Financial strength
Current ratio
3.041
Quick ratio
2.39
Long term debt to equity
0.089
Total debt to equity
0.226
Interest coverage (TTM)
-2.24%
Profitability
EBITDA (TTM)
-41.6
Gross margin (TTM)
56.58%
Net profit margin (TTM)
-7.20%
Operating margin (TTM)
-4.15%
Effective tax rate (TTM)
-62.81%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-1.92%
Return on equity (TTM)
-8.08%
Valuation
Price to revenue (TTM)
3.154
Price to book
3.41
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
-30.147
Free cash flow yield (TTM)
-3.32%
Free cash flow per share (TTM)
-0.717
Growth
Revenue change (TTM)
59.55%
Earnings per share change (TTM)
-71.88%
3-year revenue growth (CAGR)
97.65%
3-year earnings per share growth (CAGR)
-46.04%
What the Analysts think about Legend Biotech
Analyst ratings (Buy, Hold, Sell) for Legend Biotech stock.
Analyst projections of the future price of Legend Biotech stock.
Bulls say / Bears say
CARVYKTI sales reached a preliminary $710 million in Q3 2026, up from $657 million in Q2; the earlier quarter was already 50% higher year on year, with particularly rapid growth outside the US. This points to strong demand and widening access. (Stock Titan, Legend Biotech)
Five-year follow-up found that half of 20 patients in an early-line multiple myeloma study remained alive and progression-free without further treatment after one CARVYKTI infusion. If confirmed in larger studies, this durability could strengthen the case for using the therapy earlier. (Johnson & Johnson)
Legend reported encouraging first-in-human results for its in vivo CAR-T candidate LB2501: at the higher dose, six patients had a 100% response rate and an 83.3% complete response rate. It is early evidence from a very small group, but offers a possible route to growth beyond CARVYKTI. (Legend Biotech)
Competition could limit CARVYKTI’s growth: J&J’s Tecvayli-Darzalex combination has entered the same second-line multiple myeloma setting, while Gilead and Arcellx are developing another CAR-T rival. Alternatives may challenge CARVYKTI’s share even as the market expands. (Fierce Pharma)
Leadership uncertainty adds execution risk while Legend relies heavily on CARVYKTI. Oppenheimer downgraded the shares after the CEO’s departure, citing competitive pressure and lower prospects for a takeover deal. (Seeking Alpha)
Profitability may prove uneven as manufacturing scales: Q2 gross margin on product sales was 58%, but management expected it to fall to the low 50% range in Q3 before recovering in Q4. That variability makes it harder to assume rapid sales growth will translate into steadily rising profits. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Legend Biotech Financial Performance
Revenues and expenses
Legend Biotech Earnings Performance
Company profitability
Upcoming events
No upcoming events
Legend Biotech News
AllArticlesVideos
Legend Biotech taps Novartis veteran Zhang as CEO
Reuters2 months ago
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
WSJ2 months ago
Legend Biotech Q2 Earnings Call Highlights
MarketBeat3 months ago
Funds containing Legend Biotech
Fund name | Fund size | $LEGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.13% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.13% |
iShares MSCI China€ICGA | $2.7B | 0.07% |
iShares MSCI AC Far East ex-Japan€IQQF | $1.9B | 0.02% |
iShares MSCI AC Far East ex-Japan£IFFF | $1.9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.